By elucidating the molecular mechanism by which OVOL1 affects the progression of NSCLC through the cholesterol metabolism pathway, we can provide a novel therapeutic target for treating NSCLC by exploiting the vulnerability of cancer cells associated with metabolic reprogramming. This evidence concerns the gene OVOL1 and non-small cell lung carcinoma.